Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Anesiva has reported that the first patient has been treated in the Phase II study of its compound Adlea for post-operative pain in patients who undergo total hip replacement surgery, also called total hip arthroplasty.
Subscribe to our email newsletter
Adlea is a long-acting, non-opiate analgesic drug candidate designed to provide pain relief for weeks to months after a single local application during the surgical procedure.
The trial will enroll approximately 160 patients, randomized to receive either a single 15mg dose of Adlea or placebo instilled into the surgical wound prior to closure. The trial will evaluate safety, tolerability, pharmacokinetics and the ability of Adlea to reduce post-operative pain following total hip replacement surgery.
John McLaughlin, CEO of Anesiva, said: “Hip replacement surgery can involve a long recovery time sometimes up to six months which is frequently accompanied by post-operative pain from the procedure. We believe Adlea may help alleviate the resulting pain for patients without the troubling side effects that other treatments such as opiates and COX-2 inhibitors can cause. We believe that these benefits can help patients recover faster and complete their rehabilitation more successfully after surgery.”